Tempus Completes Acquisition of Ambry Genetics
Tempus AI (NASDAQ: TEM) has completed its acquisition of Ambry Genetics, a genetic testing company focused on understanding genetics-disease relationships. The transaction, valued at $600 million total, consists of $375 million in cash and $225 million in shares, with $100 million subject to a one-year lock-up period. The acquisition was financed by Ares Management Credit funds.
Tempus CEO Eric Lefkofsky emphasized that this strategic acquisition enhances their capability to deliver advanced solutions to clinicians, patients, and life sciences companies by combining diagnostics and data. Ambry Genetics will continue operating as a wholly-owned subsidiary of Tempus, maintaining its current leadership team.
Tempus AI (NASDAQ: TEM) ha completato l'acquisizione di Ambry Genetics, un'azienda specializzata in test genetici focalizzati sulla comprensione delle relazioni tra genetica e malattie. La transazione, del valore totale di 600 milioni di dollari, consiste in 375 milioni di dollari in contanti e 225 milioni in azioni, di cui 100 milioni soggetti a un periodo di lock-up di un anno. L'acquisizione è stata finanziata dai fondi di credito di Ares Management.
Il CEO di Tempus, Eric Lefkofsky, ha sottolineato che questa acquisizione strategica incrementa la loro capacità di fornire soluzioni avanzate a medici, pazienti e aziende delle scienze della vita, combinando diagnosi e dati. Ambry Genetics continuerà a operare come sussidiaria interamente controllata da Tempus, mantenendo il suo attuale team di leadership.
Tempus AI (NASDAQ: TEM) ha completado su adquisición de Ambry Genetics, una empresa de pruebas genéticas centrada en comprender las relaciones entre genética y enfermedades. La transacción, valorada en 600 millones de dólares en total, consiste en 375 millones en efectivo y 225 millones en acciones, con 100 millones sujetos a un período de lock-up de un año. La adquisición fue financiada por los fondos de crédito de Ares Management.
El CEO de Tempus, Eric Lefkofsky, enfatizó que esta adquisición estratégica mejora su capacidad para ofrecer soluciones avanzadas a clínicos, pacientes y empresas de ciencias de la vida al combinar diagnósticos y datos. Ambry Genetics continuará operando como una subsidiaria de propiedad total de Tempus, manteniendo su actual equipo directivo.
템퍼스 AI (NASDAQ: TEM)가 유전 질병 관계를 이해하는 데 중점을 둔 유전자 검사 회사인 앰블리 유전학의 인수를 완료했습니다. 총 6억 달러로 평가된 이 거래는 현금 3억 7천5백만 달러와 주식 2억 2천5백만 달러로 구성되며, 1년의 잠금 기간이 설정된 1억 달러가 포함되어 있습니다. 이 인수는 Ares Management 신용 펀드로 자금을 조달했습니다.
템퍼스 CEO 에릭 레프코프스키는 이번 전략적 인수가 임상의, 환자, 생명 과학 회사에 진단과 데이터를 결합하여 고급 솔루션을 제공할 수 있는 능력을 강화한다고 강조했습니다. 앰블리 유전학은 템퍼스의 전액 출자 자회사로 계속 운영되며 현재의 리더십 팀을 유지합니다.
Tempus AI (NASDAQ: TEM) a finalisé l'acquisition de Ambry Genetics, une société de tests génétiques axée sur la compréhension des relations entre la génétique et les maladies. La transaction, d'une valeur totale de 600 millions de dollars, se compose de 375 millions de dollars en espèces et de 225 millions de dollars en actions, dont 100 millions de dollars soumis à une période de blocage d'un an. L'acquisition a été financée par des fonds de crédit d'Ares Management.
Le PDG de Tempus, Eric Lefkofsky, a souligné que cette acquisition stratégique renforce leur capacité à fournir des solutions avancées aux cliniciens, aux patients et aux entreprises des sciences de la vie en combinant diagnostics et données. Ambry Genetics continuera de fonctionner en tant que filiale entièrement détenue de Tempus, en maintenant son équipe dirigeante actuelle.
Tempus AI (NASDAQ: TEM) hat die Übernahme von Ambry Genetics, einem auf genetische Tests spezialisierten Unternehmen, das sich auf das Verständnis von Beziehungen zwischen Genetik und Krankheiten konzentriert, abgeschlossen. Die Transaktion, die mit insgesamt 600 Millionen Dollar bewertet wird, besteht aus 375 Millionen Dollar in bar und 225 Millionen Dollar in Aktien, wobei 100 Millionen Dollar einer einjährigen Sperrfrist unterliegen. Die Übernahme wurde durch die Kreditfonds von Ares Management finanziert.
Der CEO von Tempus, Eric Lefkofsky, betonte, dass diese strategische Übernahme ihre Fähigkeit verbessert, Klienten, Patienten und Unternehmen der Lebenswissenschaften fortschrittliche Lösungen anzubieten, indem Diagnostik und Daten kombiniert werden. Ambry Genetics wird weiterhin als vollständig im Besitz von Tempus betrieben, wobei das aktuelle Führungsteam erhalten bleibt.
- Strategic acquisition valued at $600 million strengthens diagnostic capabilities
- Complementary business integration enhancing solutions for healthcare stakeholders
- Maintains operational continuity with existing Ambry leadership team
- Significant cash outlay of $375 million may impact financial flexibility
- Share issuance of $225 million leads to stockholder dilution
Insights
The $600 million acquisition of Ambry Genetics marks a pivotal expansion for Tempus in the precision medicine market, combining Tempus' AI capabilities with Ambry's established genetic testing infrastructure. The transaction structure reveals strategic financial planning:
This deal positions Tempus as a more vertically integrated player in precision medicine, combining their AI expertise with Ambry's diagnostic capabilities. The synergy potential is substantial: Ambry's genetic testing data can enhance Tempus' AI models, while Tempus' technology can optimize Ambry's testing operations and market reach.
Financing through Ares Management Credit funds indicates strong institutional confidence in the deal's potential. The decision to maintain Ambry as a subsidiary with its existing leadership team suggests a thoughtful integration approach that preserves operational continuity while allowing for strategic alignment.
The acquisition's structure and timing reflect current market conditions where cash conservation is crucial. The mixed payment method balances immediate value delivery with long-term alignment, while the credit funding demonstrates access to institutional capital markets despite tighter conditions.
This strategic acquisition creates a powerful convergence of AI and genetic diagnostics, potentially revolutionizing precision medicine delivery. The combination of Tempus' AI platforms with Ambry's extensive genetic testing capabilities creates a unique value proposition in healthcare diagnostics.
The technical synergies are compelling: Ambry's genetic testing data can significantly enhance Tempus' AI models, potentially improving diagnostic accuracy and treatment recommendations. This integration could accelerate the development of novel biomarkers and enhance patient stratification for clinical trials.
The deal strengthens Tempus' competitive position against both traditional diagnostic companies and tech-enabled healthcare providers. By incorporating Ambry's established testing infrastructure, Tempus can now offer end-to-end solutions from genetic testing to AI-driven insights, potentially reducing time-to-diagnosis and improving treatment selection.
The maintenance of Ambry's current leadership team suggests a focus on preserving operational expertise while pursuing technological integration. This approach could accelerate market adoption and minimize integration risks while maximizing the potential for innovation in precision medicine.
“This acquisition complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies,” said Eric Lefkofsky, Founder and CEO of Tempus. “We are excited to welcome Ambry to the Tempus team as we work together to improve patient outcomes and transform treatment journeys through the power of technology.”
As previously disclosed in Tempus’ third quarter 2024 results, the company paid
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ acquisition of Ambry Genetics. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203899156/en/
Erin Carron
media@tempus.com
773-612-4414
Source: Tempus AI, Inc.
FAQ
What is the total value of Tempus's acquisition of Ambry Genetics?
How much of the TEM stock payment is subject to lock-up?
Will Ambry Genetics maintain its current operations under Tempus (TEM)?
Who provided financing for Tempus's Ambry Genetics acquisition?
What is the strategic purpose of TEM's Ambry Genetics acquisition?
